Main Menu

Consultancy in oncology

Our expert consultancy work in oncology helps to further our mission to defeat cancer. It can create new partnerships with industry and deepen our existing relationships, and can enable the translation of our work into new cancer treatments.

Two scientists discussing results in the lab

As one of the UK’s leading higher education institutions in industry collaboration, we have a deep understanding of the cancer science landscape and the latest innovations in oncology.

Our scientists work in a wide range of research fields – from cancer drug discovery and development to cancer clinical trials of all types, from basic cancer biology to MedTech, medical physics and imaging, and in the development of medical devices.

Many of our faculty are members of scientific advisory boards and guideline and trial steering committees, including for major pharmaceutical companies. They frequently speak at conferences and symposia and many undertake specialist consultancy work.

They act as expert witnesses in patent defences, give expert advice on clinical trials and pre-clinical drug programmes, and review documents for patent-related activity. They also work with companies on grant writing and review.

The ICR also provides expert advice and insight into all aspects of research and development which align with our mission to defeat cancer – for example in cancer detection, treatment and patient benefit and use of research equipment.

Cancer Research Consultancy 

We offer a tailored consultancy service in oncology to industry. If you are interested in working with our cancer researchers, contact [email protected].

Esther Arwert consultancy

Dr Esther Arwert is an expert in: the tumour microenvironment, immunogenicity, cancer associated fibroblasts (CAFs), cancer immunology, class I antigen presentation, cytotoxic T cells, pre-clinical cancer models, genetically engineered mouse models (GEMMs) and spatial phenotyping. She has in-depth understanding of techniques including: TCRseq, multiplex IHC/IF, cellular assay development, immunopeptidomics, small molecule drug discovery and adoptive T cell transfer.

Visit researcher page

Rachael Natrajan consultancy

Dr Rachael Natrajan leads the Functional Genomics group in our Division of Breast Cancer. She is available for consultancy and is an expert in predictive/prognostic biomarkers, genomics, single cell and spatial genomic technologies, and functional genomic approaches for target identification. Dr Natrajan has particular expertise in DNA repair including PARP inhibitors, splicing inhibitors (eg SF3B1 and others), transcriptional inhibitors (CDK7, CDK12, CDK9 and CDK4/6), epigenetic targets (BRD, KDM etc) and immune-oncology related targets.

Visit researcher page